Renal and cardiac effects of terlipressin and dobutamin in cirrhosis and ascites. A randomised study.

Dept. of Gastroenterology, Universityhospital Odense0 个研究点目标入组 25 人开始时间: 2014年1月15日最近更新: 2020年12月7日

试验速览

暂无简介。

•-The diagnosis of cirrhosis either verified by biopsy or based on established clinical, biochemical and ultrasonographic criteria
•-Age 18-75 years
•-ultrasonic vericated ascites within 3 months prior to inclusion
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Denied consent
•- Patients under 18 or over 75 years of age
•-Acute medical conditions such as ongoing infection, acute heart or lung disease, other conflicting diseases.
•-Patients with known Heart, lung or kidney disease (ex. ischemic heart disease, heart failure, arrythmias, COLD, cronic kidney disease which is not hepatorenal syndrome, insulin dependent diabetes)
•- Cerebral or psychiatric disease resulting in patients unable to qualified consent.
•-Cancer including HCC
•-Malignant arterial hypertension > 220/120 mmHg
•-Hepatic encephalopathy > grade 2
•-Serum-creatinin > 200 µmol/L
•-Pregnancy (Urine-HCG negative within 7 days prior to inclusion in the trial) or breast feeding.
•-Alcohol withdrawal symptoms such as tremor, increasing heart rate, increasing temperature.
•-Treatment with vasoactive substances with cannot be paused 6 days prior to the trial and during the trial
•- Allergy towards dobutamine or terlipressin
•- Pheochromocytoma
•. ideopatic hypertrofic subaortic stenosis

发起方

Dept. of Gastroenterology, Universityhospital Odense